Sirtris Pharmaceuticals Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $720M

Sirtris Pharmaceuticals General Information

Description

Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. The company specializes in resveratrol formulations and derivatives as activators of the SIRT1 enzyme that help in reducing heart diseases, thereby enabling patients to have access to quality medication.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 790 Memorial Drive
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 790 Memorial Drive
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sirtris Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 05-Jun-2008 $720M Completed Generating Revenue
7. IPO 23-May-2007 Completed Generating Revenue
6. Later Stage VC (Series C1) 06-Feb-2007 Completed Generating Revenue
5. Debt - General 19-Apr-2006 Completed Generating Revenue
4. Later Stage VC (Series C) 04-Apr-2006 Completed Generating Revenue
3. Early Stage VC (Series B) 08-Mar-2005 Completed Generating Revenue
2. Early Stage VC (Series A1) 01-Dec-2004 $13M $18M Completed Product Development
1. Early Stage VC (Series A) 09-Sep-2004 $5M $5M Completed Product Development
To view Sirtris Pharmaceuticals’s complete valuation and funding history, request access »

Sirtris Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1
Series C
Series B
Series A1 21,666,667 $0.001000 $0.6 $0.6 1x $0.6 19.73%
Series A 10,000,000 $0.001000 $0.5 $0.5 1x $0.5 9.1%
To view Sirtris Pharmaceuticals’s complete cap table history, request access »

Sirtris Pharmaceuticals Patents

Sirtris Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2768833-A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Inactive 20-Oct-2011
EP-2768833-A4 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Inactive 20-Oct-2011
WO-2013059587-A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Inactive 20-Oct-2011
WO-2013059589-A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Inactive 20-Oct-2011
WO-2013059594-A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Inactive 20-Oct-2011 C07D487/04
To view Sirtris Pharmaceuticals’s complete patent history, request access »

Sirtris Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sirtris Pharmaceuticals Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bessemer Venture Partners Venture Capital Minority
Bock Family Ventures Venture Capital Minority
Cardinal Partners Venture Capital Minority
Cycad Group Venture Capital Minority
Hercules Capital (San Mateo) Lender/Debt Provider Minority
You’re viewing 5 of 14 investors. Get the full list »

Sirtris Pharmaceuticals FAQs

  • When was Sirtris Pharmaceuticals founded?

    Sirtris Pharmaceuticals was founded in 2004.

  • Where is Sirtris Pharmaceuticals headquartered?

    Sirtris Pharmaceuticals is headquartered in Cambridge, MA.

  • What is the size of Sirtris Pharmaceuticals?

    Sirtris Pharmaceuticals has 10 total employees.

  • What industry is Sirtris Pharmaceuticals in?

    Sirtris Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Sirtris Pharmaceuticals a private or public company?

    Sirtris Pharmaceuticals is a Private company.

  • What is the current valuation of Sirtris Pharmaceuticals?

    The current valuation of Sirtris Pharmaceuticals is .

  • What is Sirtris Pharmaceuticals’s current revenue?

    The current revenue for Sirtris Pharmaceuticals is .

  • How much funding has Sirtris Pharmaceuticals raised over time?

    Sirtris Pharmaceuticals has raised $181M.

  • Who are Sirtris Pharmaceuticals’s investors?

    Bessemer Venture Partners, Bock Family Ventures, Cardinal Partners, Cycad Group, and Hercules Capital (San Mateo) are 5 of 14 investors who have invested in Sirtris Pharmaceuticals.

  • When was Sirtris Pharmaceuticals acquired?

    Sirtris Pharmaceuticals was acquired on 05-Jun-2008.

  • Who acquired Sirtris Pharmaceuticals?

    Sirtris Pharmaceuticals was acquired by GSK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process